Last reviewed 2026-04-23 · How we verify

liposomal amphotericin B + paromomycin

Liposomal amphotericin B disrupts fungal cell membranes while paromomycin inhibits parasitic protein synthesis, together targeting visceral leishmaniasis parasites.

Liposomal amphotericin B disrupts fungal cell membranes while paromomycin inhibits parasitic protein synthesis, together targeting visceral leishmaniasis parasites. Used for Visceral leishmaniasis (kala-azar).

At a glance

Mechanism of action

Liposomal amphotericin B binds to ergosterol in the parasitic cell membrane, causing leakage and cell death, while paromomycin is an aminoglycoside antibiotic that inhibits protein synthesis in Leishmania parasites. This combination approach targets the parasite through complementary mechanisms to improve efficacy and reduce resistance.

Approved indications

• Visceral leishmaniasis (kala-azar)

Common side effects

• Nephrotoxicity
• Infusion-related reactions
• Hypokalemia
• Ototoxicity
• Hepatotoxicity

Key clinical trials

• Study Comparing Several Drugs to Understand Which Work Against Cutaneous Leishmaniasis (CL) (PHASE3)
• Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011) (PHASE2)
• Short Course Regimens for Treatment of PKDL (Sudan) (PHASE2)
• Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh (PHASE3)
• Combination Therapy in Indian Visceral Leishmaniasis (PHASE3)
• Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.